

– *Curriculum Vitae* –

MONIQUE L. GIROUX, MD

Position:

Medical Director, Booth Gardner Parkinson's Care Center

Prior Employment:

Cleveland Clinic, Director, Outpatient Movement Disorders Program

Professional Education and Training:

Fellow, Functional Neuroimaging of Movement Disorders
Emory University, Div. of Nuclear Medicine
Clinical Fellow, Movement Disorders, Emory University, Atlanta. GA
Administrative Chief Resident and Instructor in Neurology, Yale
Intern in Internal Medicine and Resident in Neurology, Yale
Medical Degree, Ohio State University College of Medicine

Professional Affiliations/Committees:

American Board of Psychiatry and Neurology, 1997. Recertification 2007.
American Academy of Neurology.
Movement Disorder Society.
American Society of Neurorehabilitation
American Academy of Physician Executives
International Society for Quality of Life Research
Medical Director Booth Gardner Parkinson's Center, National Parkinson's Foundation Care Center
Evergreen Neurologic Institute, Patient Community Advisory Committee
EverCare Patient Service Excellence Steering Committee, Evergreen Hospital
Chronic Care Consortium, Evergreen Hospital
Northwest Parkinson's Foundation, Board member
Medical Director National Neuroscience Alliance for Physician Assistants
Medical Faculty, National Parkinson's Foundation, Allied Health Training
Parkinson's National Training Program.

Clinical Interests:

Comprehensive care and rehabilitation for people with Parkinson's disease and related movement disorders. Extensive experience in DBS management, Botulinum toxin injections' (Botox) for dystonia and spasticity. Conditions treated include parkinsonism, gait and balance disorders, tics and Tourette's, dystonia, ataxia and tremor.

Research Interests:

To understand and develop the best ways of delivering care for people with chronic neurological conditions such a parkinsonism with emphasis on patient-centered care, respect, hope, wellness, and quality of life.

(continued)

Care Philosophy:

"I strive to partner with my patients and families so that we may find the best solution for quality of life and sense of wellness despite their medical condition. We partner with rehabilitation specialists and other team members to tailor our treatment to the unique needs of the patient. This partnership with the patient and our team allows the patient to become an active team member that can result in an increased the sense of control, motivation and hope."

Bibliography:

1. Malatynska E, Dilsaver SC, Knapp, RJ, Giroux ML, Ikeda M, Yamamura HI. "The interaction of a benzodiazepine receptor antagonist (RO 15-1788) with GABA and GABA receptor antagonists at the GABA a receptor chloride-ionophore complex." Neurochemistry International, 1991. 18:405-410.
2. Giroux ML, Malatynska E, Dilsaver SC. "Bright light does not alter muscarinic receptor binding parameters." Pharmacology Biochemistry and Behavior, 1991. 38: 695- 697.
3. Malatynska E, Giroux ML, Dilsaver SC. "Chronic in vivo amitriptyline treatment enables amitriptyline to augment GABA-stimulated chloride uptake in vivo." Pharmacology Biochemistry and Behavior, 1991. 39(2):553-556.
4. Malatynska E, Giroux ML, Dilsaver SC, Schwarzkopf SB. "Bi-directional effect of Beta-carboline agonists at the benzodiazepine-GABA a receptor chloride ionophore complex on GABA stimulated ³⁶Cl- uptake. Brain Research Bulletin, 1992. 28(4):605- 611.
5. Azizi SA, Fayad PB, Fulbright R, Giroux ML, Waxman SG. "Clivus and cervical spinal osteomyelitis with epidural abscess presenting with multiple cranial neuropathies." Clinical Neurology and Neurosurgery, 1995. 97: 239-244.
6. Giroux ML, Vitek J. "Pallidotomy- A treatment for Parkinsonian tremor? In JK Krauss, RG Grossman, J Jankovic (eds.) Pallidal surgery for the treatment of Parkinson's Disease and Movement Disorders." Lippincott-Raven: Philadelphia, 1998. 12: 179-190.
7. Giroux ML, Vitek JL. "Pathophysiology of medication related Parkinson's disease." Annals of Neurology, 2000:47(S1):S31-40.
8. Samii A, Goodkin B, Giroux ML. "Bilateral subthalamic nucleus stimulation after bilateral pallidotomies in a patient with advanced Parkinson's disease," Parkinsonism and Related Disorders, Jan. 2003:9(3): 159-62.
9. Karamohamed S. Latourelle JC. Racette BA. Perlmutter JS. Wooten GF. Lew M. Klein C. Shill H. Golbe LI. Mark MH. Guttman M. Nicholson G. Wilk JB. Saint-Hilaire M. DeStefano AL. Prakash R. Tobin S. Williamson J. Suchowersky O. Labell N. Growdon BN. Singer C. Watts R. Goldwurm S. Pezzoli G. Baker KB. Giroux ML. Pramstaller PP. Burn DJ. Chinnery P. Sherman S. Vieregge P. Litvan I. Gusella JF. Myers RH. Parsian A. "BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study." Neurology. 65(11):1823-5, 2005 Dec 13.
10. Wilk JB, Tobin JE, Suchowersky O, Shill H, Klein C, Wooten GF, Lew M, Mark MH, Guttman M, Watts RL, Singer C, Growdon J, Latourelle JC, Saint-Hilaire M, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker K, Giroux ML, Litvan I, Pramstaller PP, Nicholson GA, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI. "Herbicide Exposure Modifies GSTP1 Haplotype Association to Parkinson Onset Age: The Gene PD Study". Neurology 2006: 67: 2206-2210.
11. Giroux, ML, Parkinson's disease: "Treating the whole patient." Cleveland Clinic Journal 2007: 74: 313-328.
12. Farris S , Giroux, ML. "Gait changes after Deep Brain Stimulation for Parkinson's Disease in a patient with cervical myelopathy." Accepted Neurorehabilitation 2007.

13. Giroux ML, Farris, S. "Treating Parkinson's disease: The impact of different care models on quality of life." Topics in Geriatric Rehabilitation 2008: 24:83-89.

14. Farris S, Ford P, Giroux ML. "Deep Brain Stimulation and the Ethics of Protection and Caring for the Patient with Parkinson's Dementia." (Submitted Lancet Neurology 2007)

15. Farris, S, Giroux ML. "Deep brain stimulation hardware complications: The Role of Electrode Impedance Measurements." Accepted Movement Disorders 2008

16. Pandya M, Kubu C, Giroux ML. "The many faces of Parkinson's disease: not just a movement disorder." (Submitted Cleveland Clinic Journal 2008)

ABSTRACTS:

1. Giroux ML, Malatynska E, Dilsaver SC. "Bright light does not affect muscarinic acetylcholine receptor binding." Ohio Academy of Science, 1989.

2. Giroux ML, Vitek JL, Grafton ST, DeLong MR, Hoffman JM. "The role of FDG-PET in pre-operative evaluation of Parkinson's disease and effect of pallidotomy." Neurology, 1997. 48: A25 1.

3. Hoffman JM, Shi B, Goodman MM, Thyagarajan S, Giroux ML, Levey AL, Watts, RL. "Correlation of in-vivo and in-vitro dopamine transporter function." Neurology, 1997. 48: A62.

4. Giroux ML, Shi B, Subramanian T, Miller G, Greenamyre JT, Bakay RAE, Levey AI, Watts RL, Camp M, Huerkamp MI, Votaw J and Hoffman JM. "Correlation of dopamine transporter distribution and binding measured in-vivo with PET and in-vitro with autoradiography." Journal of Cerebral Blood Flow and Metabolism, 1997. 17: S6.

5. Hoffman JM, Giroux ML, Vitek JL, Grafton ST and DeLong NM. "Altered glucose metabolism in Parkinson's Disease." Journal of Cerebral Blood Flow and Metabolism, 1997. 17: S692.

6. Farris, S, Giroux, ML, Vitek, JV. "Rivastigmine in Dementia Associated with Idiopathic Parkinson's disease;" Volume 19, Issue S9 (2004) Supplement: 8th International Congress of Parkinson's disease and Movement Disorders

7. Goodman MM, Shoup TM, Cullom SJ, Votaw JR, Shi B, Olson J, White M, Votaw D, Eshima D, Giroux ML, Garcia EV, Hoffman JM. "Initial Evaluation of High Energy Na-Based Coincidence Brain Imaging of Tumor Amino Acid Uptake and Striatal Dopamine Transporters with [F- 18]FECNT." J Nuclear Medicine, 1997. 38(5): 152P.

8. Deterding T, Votaw JR, Goodman mm, Eshima DE, Eshima L, Maveaux E, Camp VM, Shi BZ, Votaw DB, Giroux ML, Hoffman JM. "Biodistribution and Dosimetry of Dopamine Transporter Ligand and FECNT." (Submitted)

9. Giroux ML, Grafton ST, Vitek JL, Votaw JR, DeLong MR, Hoffman JM. "Effect of Pallidotomy on Cerebral Metabolism in Parkinson's Disease." NeuroImage, 1998. 7(4): S999.

10. Giroux ML, Votaw JR, Galt J, Kilts C, Martarello L, Goodman MM, Watts RL, Hoffman JM. "Dopamine Transporter Quantification Using a new F Ligand and Coincidence SPECT Imaging." Movement Disorders: Official Journal of the Movement Disorder Society, 1998. 13(2): 239.

11. Giroux ML, Hoffman JM. "Medication related changes in Cerebral Glucose Metabolism in Parkinson's Disease." NeuroImage, 1998. 7(4): S237.

12. Giroux ML, Turner RS, Vitek JL, DeLong MR, Hoffman JM, Grafton ST. "Effect of Subthalamic Deep Brain Stimulation on Motor-Related Cerebral Activity Measured by PET in Parkinson's Disease." Movement Disorders: Journal of the Movement Disorder Society, 1998. 13(2): 297.
13. Sammi A, Giroux ML, Slimp JC, Goodkin R. "Bilateral subthalamic nucleus stimulation after bilateral pallidotomies in a patient with advanced Parkinson's disease". Parkinsonism and Related Disorders 2001;7(suppl):S85.
14. Daniel, S and Giroux, ML. "Rivastigmine improves cognition in a patient with Idiopathic Parkinson's disease," National Conference of the American Academy of Physician Assistants, 2001.
15. Farris S, Giroux ML, Vitek J. "Safety and efficacy of rivastigmine in Parkinson's disease patient's with dementia, a retrospective review." Movement Disorders 2004, S274.
16. Lee JYK, Machado A, Deogaonkur M, Kubu C, Farris S, Giroux M, Vitek J, Rezai A. "Thalamic Deep Brain Stimulation for Tourette's Syndrome." International Society of Reconstructive Neurosurgery, Seoul, South Korea, September 1-3, 2005.
17. Kubu, CS, Giroux, ML, Rezai, AR. "Depression and memory following DBS in Patients with Parkinson Disease." International Neuropsychological Society, " Feb. 2007.
18. Rueda-Acevedo, M; Farris, S; Senatus, P; Giroux, ML. "Controlling dyskinesias in Parkinson's disease patients with STN/DBS new programming strategy." American Academy of Neurology 2007.